Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NRC Group ASA - Appointed to major rail contract in Norway - NOK 436 million

Bane Nor has appointed NRC Norge AS, a company wholly owned by NRC Group ASA, to a contract for rehabilitation and upgrading of the catenary infrastructure on the railway between Hønefoss and Nesbyen.  The contract is appointed to a joint venture together with Nettpartner, and NRC’s share is valued at approximately NOK 436 million. The contract will involve rail services such as electro, signal/telecom, track and groundwork. The work will commence in March 2024 and is scheduled for completion in autumn 2027. Closing date for submission of complaints is 10 days from today, and formal

Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development

Cereno Scientific (Nasdaq First North: CRNO B) today announced that Julia Fransson has joined the company as Director of Business Development. She joins the clinical stage biotech at an exciting point of the company’s growth journey, in developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 in phase II in orphan disease PAH which is to deliver top line study results by Q2 this year.“As our innovative portfolio of candidate drugs are progressing well, we need to scale our capacity on the business development side of our operations. Julia

The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM

Ahead of the Annual General Meeting 2024, The Nomination Committee proposes that the Board of Directors, for the period until the end of the next AGM, shall consist of seven members elected by the Annual General Meeting without alternates.Humana's Nomination Committee prior to the 2024 AGM consists of Fredrik Strömholm, appointed by Impilo Care AB (Chairman of the Nomination Committee), Alexander Kopp, appointed by Incentive AS, Richard Torgerson, appointed by Nordea Funds, Anette Andersson, appointed by SEB Investment Management AB and Anders Nyberg, Humana’s Chairman of the Board.

Comment from the Board of Directors of Biokraft International AB (publ) about the mandatory tender offer from 1Vision Biogas

1Vision Biogas AB (“1Vision Biogas”) has today announced a mandatory cash tender offer for the shares in Biokraft International AB (publ), reg.no 556528-4733 (“Biokraft” or the “Company”) at a price of SEK 20.65 per share (the “Offer”). The Offer is made due to 1Vision Biogas’ shareholding in Biokraft, following Aneo Renewables Holding AS and St1 Sverige AB consolidated their respective shareholding in Biokraft into the newly established and jointly owned company 1Vision Biogas, which now corresponds to approximately 55 per cent of the total number of shares and votes in the Company.

UPM-Kymmene Corporation: Managers’ Transactions (Manner)

UPM-Kymmene Corporation                Managers’ Transactions                        2 February 2024 at 16:15 EET UPM-Kymmene Corporation: Managers’ Transactions (Manner) UPM-Kymmene Corporation has on 2 February 2024 received the following notification: ____________________________________________Person subject to the notification requirementName: Topi MannerPosition: Member of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64Notification type: INITIAL NOTIFICATION____________________________________________Transaction date: 2024-02-02Venue:

Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform

STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Company”), a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Continuing on Impilo’s long-term ambitions of building a leading Northern European OTC/Rx platform, and the work through Mallax, Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth. Avia was founded in 2016 and focuses on medically positioned products

#24-10 Unit issue in Eurobattery Minerals AB

Information regarding the last day of trading in paid subscribed units and the first day of trading in warrants issued by Eurobattery Minerals AB The unit issue in Eurobattery Minerals AB (“The Company”) is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscribed units has been set for February 7, 2024.   The first day of trading for the Company’s warrants series 4 and 5 (TO4 and TO5) has been set for February 13, 2024.   Information regarding the affected instruments:   Listing name: Eurobattery Minerals BTU

CS MEDICA A/S Achieves New Milestone with Patent on their Wound Care Treatment.

CS MEDICA received its third-issued patent on its "Wound Gel," offering an advanced healing process for wounds such as minor abrasions, cuts, burns, and sunburns.CS MEDICA A/S ("CS MEDICA" or "The Company"), an innovator in the healthcare industry, is proud to announce the recent patent approval for its Wound Gel, marked by the Danish Patent and Trademark Office under patent number DK 181458.  This achievement is the third patent granted to CS MEDICA in the past year, reinforcing the company's commitment to innovation in healthcare. Moreover, the company has advanced its research and

SAGAX INVESTS SEK 692 MILLION THROUGH 7 TRANSACTIONS

Sagax has through 7 separate transactions acquired 8 properties for the equivalent of SEK 692 million. The properties comprise a lettable area of 55,400 square metres and 117,100 square metres of land, whereof 29,000 square metres leasehold. The annual rental income amounts to the equivalent of SEK 81 million. The occupancy rate is 99% and the average remaining lease term is 9.2 years. Closing for the equivalent of SEK 599 million has taken place during the first quarter of 2024. Closing for the remaining SEK 93 million is expected to take place during the end of the first quarter of

Allgon Export opens its doors to new partners

Continuing Allgon’s plan to consolidate its resources into a single and stronger force, Tele Radio Export has been transformed into Allgon Export. The subsidiary will continue with strategic expansion into new markets, now with the full product lines of both subsidiary brands, Tele Radio and Åkerströms. Operations under the new organization officially begin in February 1[st], 2024.Pär Wahlstrand resumes his role under this new brand name as the General Manager of Allgon Export, based in the same location in Gothenburg. With over 15 years of experience in business development and 7 within

Norse Atlantic ASA: New share capital registered

Arendal, 2 February 2024: Reference is made to the stock exchange notice by Norse Atlantic ASA (the "Company") on 25 January 2024 regarding the final results of subsequent offering and allocation of new shares in the Company (the "Subsequent Offering"). The share capital increase pertaining to the issuance of the shares in the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises: Share capital: NOK 642,619,200 Total number of shares: 128,523,840 Nominal value per share: NOK 5 For further information, please contact: Investors: CFO,

#24-09 Unit issue in Coegin Pharma AB

The board of Coegin Pharma AB (the “Company”) has decided on a unit issue with preferential rights for the Company’s existing shareholders subject to approval from an extra general meeting, to be held on February 5, 2024. The last day of trading in the Company’s shares including the right to receive unit rights is February 5, 2024. The first day of trading in the Company’s shares excluding the right to receive unit rights is February 6, 2024. The record date is February 7, 2024. The shareholders of the Company will receive seven (7) unit rights for each ten (10) shares held per the

Invitation to a Press Conference on Bittium Corporation’s Financial Statement Bulletin 2023

Bittium CorporationPress Release Invitation to a Press Conference on Bittium Corporation’s Financial Statement Bulletin 2023 Bittium Corporation’s Press Release on February 2, 2024, at 3.00 pm (CET+1) Bittium Corporation’s Financial Statement Bulletin 2023 will be published on Friday, February 9, 2024, at 8.00 am (CET+1). The release will be available on company’s website www.bittium.com immediately after the publication. Bittium will hold a webcast for media, analysts and institutional investors on Friday, February 9, 2024, at 9.00 am (CET+1). The webcast will be held in

First US clinical cases successfully conducted with EndoDrill GI

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared motorized endoscopic core biopsy instrument, announces that the first US clinical procedures with EndoDrill[®] GI have successfully been performed by Dr Antonio Mendoza Ladd and his team at UC Davis Health, Sacramento, California. BiBB received 510(k) clearance from the US FDA for EndoDrill[®] GI in 2023 and clinical marketing activities will continue in the US.BiBB’s CEO Fredrik Lindblad and founder Dr Charles Walther were present when Dr Antonio Mendoza Ladd,

poLight ASA – New customer confirms release of two new barcode scanner products using TLens®

Horten, 2 February 2024: poLight ASA (OSE: PLT) today announced that Action Prowave Technology Co. Ltd. has confirmed it is using TLens® autofocus solution in the company’s two latest barcode scanners for industrial and logistic warehouse applications, named AW300DP and AW550 respectively. A purchase order worth approximately NOK 200,000 has been received to cover the initial mass production demand. “This will be the 11[th] barcode product to use our unique TLens® divided between six companies. This market is strategically important for the company. Although it will take time to build

Changes in Solteq Plc’s Executive Team

Stock Exchange BulletinChanges board/management/ auditorsFebruary 2, 2024, at 2:15 p.m.The composition of the Executive Team of Solteq Plc changes as of February 2, 2024. With the change, Kari Lehtosalo, the company’s CFO and member of the Executive Team since 2019, will step down from his position by mutual agreement. The Board of Directors of Solteq Plc has appointed LL.M. Mikko Sairanen (b. 1985) as the company’s new CFO. He will also continue in his role as the company’s General Counsel. "I want to thank Kari for the shared years during which he has steered the company's

Fiven ASA publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

Fiven ASA ("Fiven") has issued a senior secured sustainability-linked floating rate bond loan of EUR 110,000,000, within a total framework amount of EUR 170,000,000, on the Nordic bond market. The bonds carry a floating interest rate of EURIBOR 3m + 6.70 per cent. per annum and matures 11 December 2026. Fiven has applied for listing of the bonds on the Corporate Bond list at Nasdaq Stockholm. The bonds will be admitted to trading at Nasdaq Stockholm as soon as possible.   In connection with this, Fiven Company has prepared a prospectus. The prospectus has been approved by the

Year-end report January – December 2023

· Rental income increased 18 per cent to SEK 4,818 million (4,073). · Profit from property management increased 2 per cent to SEK 2,345 million (2,309). · Changes in the value of properties amounted to SEK -5,287 million (589). · Changes in the value of financial instruments amounted to SEK -225 million (251). · Loss after tax for the year amounted to SEK -2,721 million (2,563). · The market value of the properties amounted to SEK 82,624 million (84,879). · During the year, SEK 2,825 million (3,809) was invested in the existing property portfolio. · During the year, 8

Eevia Health Plc received a 112 KSEK / 10 KEUR sales order for a Bilberry extract product

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 10 KEUR sales order from a US company for Feno-Myrtillus 25 organic, an organically certified bilberry extract.The customer is a medium-sized US brand holder with distribution throughout North America. The sales value to Eevia of this new order is kEUR 10 and the product is in stock. The product is Eevia’s branded ingredient Feno-Myrtillus® 25 Organic, which is a highly concentrated and organically certified bilberry extract with 25% anthocyanins. “It is the first order from this customer. Although the order is small, we are a

UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth)

UPM-Kymmene Corporation                Managers’ Transactions                2 February 2024 at 14:00 EET UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth) UPM-Kymmene Corporation has on 2 February 2024 received the following notification:____________________________________________Person subject to the notification requirementName: Henrik EhrnroothPosition: Chair of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64Notification type: INITIAL NOTIFICATION____________________________________________Transaction date: 2024-02-02Venue: NASDAQ

Dolphin Drilling – further part payments from GHL received

Oslo, 2 February 2024 Dolphin Drilling AS (Dolphin Drilling, OSE: DDRIL) announces part payment received from General Hydrocarbons Limited (GHL) related to remaining past due payments. Reference is made to the Dolphin Drilling Q3 financial report from November 28 2023, where we informed of GHL past due payments representing net USD 17.3 million. Dolphin Drilling received today USD 3 million that brings the total collected since the date of Q3 2023 reporting to USD 5.5 million. ENDS For further information, please contact: Ingolf Gillesdal, Corporate Finance and Investor

Neuroendocrine prostate cancer could be restored to a state that responds to treatment

It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells. A recent study by the University of Eastern Finland found that this protein, DPYSL5, is expressed in neuroendocrine prostate cancer. Prostate cancer is the most common cancer in men, and the second most common cause of cancer death in Western countries. The growth of prostate cancer often depends on androgens, and the effect of androgens is sought to be reduced by drug therapy, especially in metastatic prostate cancer.

Report from the extraordinary general meeting in Speqta AB (publ) on 2 February 2024

At the extraordinary general meeting in Speqta AB (publ), reg. no. 556710-8757 (the “Company”) on 2 February 2024, the following resolutions, among others, were adopted. For more detailed information on the content of the resolutions, please refer to the notice of the extraordinary general meeting that has previously been published and is available on the Company's website, www.speqta.com. Election of new board member It was resolved in accordance with major shareholders' proposal to dismiss Lisa Gunnarsson at her own request and to elect Fredrik Lindros as new board member of

Hunter Group ASA - Extraordinary General Meeting held on 2 February 2024

Oslo, 2 February 2024 The Extraordinary General Meeting ("EGM") in Hunter Group ASA (the "Company") took place today on 2 February 2024 at 10:00 hours CET. All resolutions were passed in accordance with the proposals set out in the notice for the EGM, including: - Item 4: Approval of private placement of up to NOK 124m - Item 5: Approval of private placement of up to NOK 10m - Item 6: Approval of private placement of up to NOK 25m - Item 7: Approval of authorization to the Board to increase the share capital - Item 8: Election board of directors The minutes from the EGM

There are no items matching the current filter
There are no more items matching the current filter
Back to top